| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/07/2007 | CN1302811C Externally-applicated chewing gum including chip-like center |
| 03/07/2007 | CN1302807C Biological degradable macromolecule microspheres of carrying insulin and preparation method |
| 03/07/2007 | CN1302781C Target magnetic nano drug for treating leucosis and producing method thereof |
| 03/07/2007 | CN1302780C Use of alkyl phosphocholines in preparation of medicine used with antitumor medicaments |
| 03/07/2007 | CN1302771C 2-(4-isobutylphenyl) propionic acid medicinal composition |
| 03/07/2007 | CN1302764C Vaginal gel tablets |
| 03/06/2007 | US7186825 Polyamines for treatment of diseases such as cancer or treatment of tumors |
| 03/06/2007 | US7186820 Antibody for use in the treatment of rheumatic and osteoarthritis |
| 03/06/2007 | US7186813 Biomolecules having multiple attachment moieties for binding to a substrate surface |
| 03/06/2007 | US7186797 Stability in blood ; complexing using compound containing phosphate group |
| 03/06/2007 | US7186755 Carboxyvinylpolymer neutralized as a gel-forming agent or a polyacrylamide-isoparaffin and ethanol, isopropanol or diethylene glycol monoethyl ether as a solvent |
| 03/06/2007 | US7186751 anticarcinogenic agents comprising a mixture of taxol, solubilizers, stabilizers and anhydrous ethanol, having superior solubility, stability, bioavailability and side effect reduction |
| 03/06/2007 | US7186724 central nervous system disorders; psychological disorders; Parkinson's disease; Huntington's disease ; sleep disorders |
| 03/06/2007 | US7186703 Derivatives of branched-chain lipophilic molecules and uses thereof |
| 03/06/2007 | US7186701 Dehydrating agent and method for dehydrating moist article using the agent and dehydrated article obtained by the method |
| 03/06/2007 | US7186697 Delivery system contains a fusion protein having a target moiety and a nucleic acid binding moiety, and a nucleic acid sequence bound to the nucleic acid binding moiety of the fusion protein. The target moiety can be an antibody or a |
| 03/06/2007 | US7186695 Administering organic arsenic compounds such as 4-(N-(S-glutathionylacetyl)amino)phenylarsenoxide for prophylaxis of degenarative joint disease; antiarthritic agents |
| 03/06/2007 | US7186687 for topical administration of peptide copper complex with corticosteroids, coal tar, anthralin, calcipotriene, and tazarotene; dermatology; cosmetics |
| 03/06/2007 | US7186686 Formulated composition |
| 03/06/2007 | US7186459 Holding capability for hydrophilic and lipophilic drugs, water-soluble and hydrophobic substaces; controlling sustained release |
| 03/06/2007 | US7186419 Polyacrylamide hydrogel for arthritis |
| 03/06/2007 | US7186416 Foamable pharmaceutical compositions and methods for treating a disorder |
| 03/06/2007 | US7186415 Cosmetics; dermatology; boron nitride particles coated with polydimethylsiloxane |
| 03/06/2007 | US7186414 Improved bioavailability; for oral and intracolonic administration |
| 03/06/2007 | US7186413 Hydrogels and water soluble polymeric carriers for drug delivery |
| 03/06/2007 | US7186411 Vaccines absorbable by the transmucosal way |
| 03/06/2007 | US7186402 Medicinal aerosol compositions with an amide and/or ester containing excipient compound |
| 03/06/2007 | US7186401 comprises magnesium stearate for improved storage stability; inhalers |
| 03/06/2007 | CA2355313C Controlled-release biocompatible ocular drug delivery implant devices and methods |
| 03/06/2007 | CA2353847C Pulmonary drug delivery |
| 03/06/2007 | CA2312493C Novel suppository form comprising an acid-labile active compound |
| 03/06/2007 | CA2268626C Pharmaceutical composition for rapid suspension in aqueous media |
| 03/06/2007 | CA2200986C Medicaments |
| 03/06/2007 | CA2132833C Hepatitis vaccines containing 3-o-deacylated monophosphoryl lipid a |
| 03/02/2007 | CA2554859A1 A process for preparing an injectable sterile pharmaceutical formulation containing at least piperacillin sodium and tazobactam sodium active principles |
| 03/01/2007 | WO2007024536A2 Process for preparing maytansinoid antibody conjugates |
| 03/01/2007 | WO2007024311A1 Acetylcysteine composition and uses therefor |
| 03/01/2007 | WO2007024026A1 Biodegradable nanoparticle having t-cell recognizable epitope peptide immobilized thereon or encapsulated therein |
| 03/01/2007 | WO2007023930A1 Brain-migrating cell and use thereof |
| 03/01/2007 | WO2007023816A1 Method for preparation of reduced keratin, reduced cuticle protein or mixture thereof |
| 03/01/2007 | WO2007023800A1 Foods |
| 03/01/2007 | WO2007023791A1 Preparation for external use |
| 03/01/2007 | WO2007023729A1 Sustained-release preparation |
| 03/01/2007 | WO2007023495A2 Method for production of single- and multi-layer microcapsules |
| 03/01/2007 | WO2007022924A2 Pharmaceutical compositions with melting point depressant agents and method of making same |
| 03/01/2007 | WO2007022813A2 A METHOD FOR PREPARING A STABLE IMMUNOGENIC PRODUCT COMPRISING ANTIGENIC HETEROCOMPLEXES OF TNFα AND A CARRIER PROTEIN |
| 03/01/2007 | WO2007022645A1 Catechol functionalized polymers and method for preparing them |
| 03/01/2007 | WO2007002780A3 Topical preservative compositions |
| 03/01/2007 | WO2007002345A3 Method for improving water solubility of chitosan |
| 03/01/2007 | WO2006128460A3 Pegylated g-csf polypeptides and methods of producing same |
| 03/01/2007 | WO2006100489A3 A transdermal topical composition and its uses |
| 03/01/2007 | WO2006086992A3 Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands |
| 03/01/2007 | WO2006077146A3 Method for producing albumin conjugates containing gyrase inhibitors |
| 03/01/2007 | WO2005119255A3 Constrained cis-diol-borate bioconjugation system |
| 03/01/2007 | WO2005094377A3 Agent eluting bioimplantable devices and polymer systems for their preparation |
| 03/01/2007 | WO2005089224A3 iRNA AGENTS TARGETING VEGF |
| 03/01/2007 | WO2005011610A3 Neurodegenerative protein aggregation inhibition methods and compounds |
| 03/01/2007 | US20070050855 Immunoglobulin fusion comprising blood glycoprotein with reduced glycosylation for use in prevention and treatment of septic shock, cachexia, viral and parasitic infection, autoimmune, arthritic and/or graft rejection |
| 03/01/2007 | US20070049552 Fluoroquinolone formulations and methods of making and using the same |
| 03/01/2007 | US20070049550 Hybrid immunomodulatory peptide and nucleotide sequences for treating allergies |
| 03/01/2007 | US20070049546 Substituted, non-coding nucleic acid molecule for therapeutic and prophylactic stimulation of the immune system in humans and higher animals |
| 03/01/2007 | US20070049519 Bactericides with antibacterial activity and an improved mammalian safety profile; exhibit reduced tissue accumulation and/or nephrotoxicity when administered to mammals |
| 03/01/2007 | US20070049516 Use of Insulin for the Treatment of Cartilaginous Disorders |
| 03/01/2007 | US20070048837 Site specific protein modification |
| 03/01/2007 | US20070048737 Calcium phosphate ceramics and particles for in vivo and in vitro transfection |
| 03/01/2007 | US20070048378 Nanoparticulate anticonvulsant and immunosuppressive compositions |
| 03/01/2007 | US20070048363 chemotherapeutical agent comprising cis-diammoniumdichloro-trans-dihydroxoplatinum(IV) or salts and/or derivatives thereof in the form of capsules, tablets, creams, ointments and infusion solutions; antitumor agents |
| 03/01/2007 | US20070048332 Stabilized liquid anti-RSV antibody formulations |
| 03/01/2007 | US20070048328 treating a food allergy; orally administer 100 mu g/kg or more of transforming growth factor-beta (TGF- beta ); no side effects |
| 03/01/2007 | US20070048326 Compositions and Methods for the Diagnosis and Treatment of Tumor |
| 03/01/2007 | US20070048300 Antibodies having altered effector function and methods for making the same |
| 03/01/2007 | US20070048299 Methods of inducing an immune response |
| 03/01/2007 | US20070048287 Molecular antigen array |
| 03/01/2007 | US20070048283 Exposing to immunogenic portion of protein and/or encoding nucleotide homologenous to sequence 20 or 22b; eliciting response to 74P3B3 protein; pancreatic cancer |
| 03/01/2007 | US20070048218 Compositions and Methods for the Diagnosis and Treatment of Tumor |
| 03/01/2007 | DE202004021169U1 Pharmazeutische Formulierung, die Lanthanverbindungen enthält A pharmaceutical formulation containing lanthanum compounds |
| 03/01/2007 | DE102005039154A1 Bioabbaubare Polymere für den Transport von Nukleinsäuren in Zellen Biodegradable polymers for the delivery of nucleic acids into cells |
| 03/01/2007 | CA2794554A1 Process for preparing antibody maytansinoid conjugates |
| 03/01/2007 | CA2622904A1 Self-assembling nanoparticles for the treatment of vascular diseases |
| 03/01/2007 | CA2620343A1 Process for preparing antibody maytansinoid conjugates |
| 03/01/2007 | CA2620259A1 Sustained-release preparation |
| 03/01/2007 | CA2620026A1 Method for production of single- and multi-layer microcapsules |
| 03/01/2007 | CA2619715A1 Pharmaceutical compositions with melting point depressant agents and method of making same |
| 03/01/2007 | CA2619601A1 Long acting injectable parasiticidal formulations |
| 03/01/2007 | CA2619568A1 Topical formulations of histone deacetylase inhibitors and methods of using the same |
| 03/01/2007 | CA2619441A1 Acetylcysteine composition and uses therefor |
| 03/01/2007 | CA2609572A1 A method for preparing a stable immunogenic product comprising antigenic heterocomplexes of tnf.alpha. and a carrier protein |
| 02/28/2007 | EP1757701A1 Methods and compositions for prolonging elimination half-times of bioactive compounds |
| 02/28/2007 | EP1757617A1 Ret Ligand (RetL) for stimulating neural and renal growth |
| 02/28/2007 | EP1757314A1 Functionalized derivatives of hyaluronic acid, formation of hydrogels and in situ using same |
| 02/28/2007 | EP1757312A1 Freeze-dried composition of inactivated virus envelope with membrane fusion activity |
| 02/28/2007 | EP1757311A2 Methods and compositions for prolonging elimination half-times of bioactive compounds |
| 02/28/2007 | EP1757310A1 Surface-modified and solubility-improved hard capsule |
| 02/28/2007 | EP1757309A1 Adhesive material |
| 02/28/2007 | EP1757308A1 Preparation for oral administration |
| 02/28/2007 | EP1757305A2 Individualized anti-cancer antibodies |
| 02/28/2007 | EP1757293A1 Bh4-responsive hyperphenylalaninemia remedies |
| 02/28/2007 | EP1757291A2 Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof |
| 02/28/2007 | EP1757281A2 Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
| 02/28/2007 | EP1757280A1 Transdermal patch for administering sufentanyl |